Diagnosing disease using a single biomarker has been very frustrating to clinicians and researchers. The widely (FDA approved) Prostate Specific Antigen (PSA) is a widely contested “marker” for prostate cancer. However, PSA alone is not very specific – in order to make the diagnosis of prostate cancer in a patient, a physician typically adds more tests for other markers to improve its accuracy. The same holds true in many other diseases, such as Diabetes Mellitus (DM).
The work of the TEIS Diabetes group is to develop sensors for monitoring and managing DM using a modified Electrochemical Impedance Spectroscopy (EIS) technique in which multiple biomarkers can be quantified simultaneously in a process called Tunable EIS (TEIS). These biomarkers include:
- Glycated hemoglobin , (HbA1c)
- Interleukin-2 receptor protein A ,(IL-2RA)
- hsC-reactive protein, (hsCRP)
By combining several of these biomarkers and a modified a device can be developed that monitors DM across several indications allowing for a more specific, sensitive monitor that needs to be used less often and is user-friendly. In order to do this, some markers might require tuning of the EIS spectra through modifying the instrumentation to allow for simultaneous perturbation at multiple frequencies (see image below). Signal processing would then be used to analyze the data to see which markers were detected. This research would positively impact the Biological and Human Systems Challenge by aligning with its goals to improve the quality of life.
MultiMarker IEEE, Aaron Fairchild and Dr. Jeffery La Belle, 2009
Related Intellectual Property
See AzTE’s (M09-135L ) Method and Device for Tuning Multiplexed Markers for Disease Assay
For more information regarding this technology contact:
Jeremy W. Burdon, Ph.D.
Director of Intellectual Assets